靜脈鐵劑市場規模、佔有率、成長分析、按產品類型、按適應症、按分銷管道、按地區 - 產業預測，2025-2032 年

2023年靜脈注射鐵劑市場規模為32億美元，從2024年的34.7億美元成長到2032年的66.1億美元，預計複合年成長率為8.4%。

全球靜脈鐵劑市場正在經歷顯著成長，這主要是由於缺鐵性貧血盛行率不斷上升，影響了很大一部分人口。缺鐵性貧血會導致攜氧能力下降，導致疲勞和認知功能障礙等症狀。人口老化進一步推動市場需求，因為老年人由於飲食限制和慢性病等因素更容易缺鐵。靜脈鐵劑治療提供了口服補充品的有效替代方案，可確保快速緩解症狀並改善患者的治療效果。市場開發公司在研發方面投入巨資，以開發創新配方並提高安全性，並進行策略合作以擴大其產品線和市場範圍。隨著意識和需求的增加，市場有望繼續擴大。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 抑制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析

靜脈注射鐵劑市場規模：依產品類型分類

• 市場概況
• 聚葡萄糖鐵
• 蔗糖鐵
• Ferric carboxymaltose
• 其他產品類型

靜脈鐵劑市場規模：依適應症分類

• 市場概況
• 慢性腎臟病
• 發炎性腸道疾病
• 癌症
• 其他疾病

靜脈鐵劑市場規模：依通路分類

• 市場概況
• 醫院藥房
• 零售藥房
• 網路藥房

靜脈鐵劑市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2022-2024）

主要企業簡介

• Sanofi（France）
• Pharmacosmos A/S（Denmark）
• AbbVie Inc.（United States）
• Daiichi Sankyo Company, Ltd.（Japan）
• Pfizer Inc.（United States）
• Zydus Lifesciences Limited（India）
• Fresenius SE & Co. KGaA（Germany）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Akebia Therapeutics, Inc.（United States）
• Rockwell Medical, Inc.（United States）
• American Regent, Inc.（United States）
• AdvaCare Pharma（United States）
• Bayer AG（Germany）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Novartis AG（Switzerland）
• Shield Therapeutics plc（United Kingdom）
• Galenica Ltd.（Switzerland）
• CSL Limited（Australia）
• AMAG Pharmaceuticals, Inc.（United States）
• Covis Pharma GmbH（Switzerland）

結論和建議

Intravenous Iron Drugs Market size was valued at USD 3.2 Billion in 2023 and is poised to grow from USD 3.47 Billion in 2024 to USD 6.61 Billion by 2032, growing at a CAGR of 8.4% during the forecast period (2025-2032).

The global intravenous iron drugs market is witnessing significant growth, primarily driven by the rising incidence of iron deficiency anemia, which affects a considerable portion of the population. This condition leads to decreased oxygen-carrying capacity, resulting in symptoms like fatigue and cognitive impairment. The aging demographic further fuels market demand, as older adults are more prone to iron deficiency due to factors such as dietary limitations and chronic illnesses. Intravenous iron therapy provides an efficient alternative to oral supplements, ensuring quicker relief and better patient outcomes. Market players are investing heavily in research and development to create innovative formulations and enhance safety, collaborating strategically to broaden their product lines and market reach. As awareness and demand increase, the market is poised for continued expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Intravenous Iron Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Intravenous Iron Drugs Market Segmental Analysis

Global Intravenous Iron Drugs Market is segmented by product type, indication, distribution channel and region. Based on product type, the market is segmented into Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, and Other Product Types. Based on indication, the market is segmented into Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Diseases. Based on distribution channel, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Intravenous Iron Drugs Market

The intravenous iron drugs market is significantly driven by the rising incidence of iron deficiency anemia globally. This condition is particularly prevalent among specific groups, including pregnant women, women of childbearing age, and individuals suffering from chronic illnesses. As awareness regarding the serious implications of iron deficiency continues to grow, coupled with the proven efficacy of intravenous iron therapies in effectively addressing this issue, there has been an upsurge in demand for these treatments. This heightened recognition and the ongoing need for effective solutions to combat iron deficiency anemia are key factors propelling the expansion of the intravenous iron drugs market.

Restraints in the Intravenous Iron Drugs Market

One significant restraint affecting the intravenous iron drugs market is the potential for adverse reactions or side effects during administration. Although these drugs are largely regarded as safe, the possibility of hypersensitivity reactions and infusion-related complications exists, including allergic responses, hypotension, and anaphylaxis. The fear of these adverse events may dissuade both healthcare professionals and patients from opting for intravenous iron therapy, thus restricting market growth. To address this challenge, it is crucial for manufacturers and healthcare providers to implement stringent patient selection criteria, effective monitoring, and careful administration protocols, all aimed at reducing the risk of complications and ensuring patient safety.

Market Trends of the Intravenous Iron Drugs Market

The intravenous iron drugs market is witnessing a significant trend towards innovation, characterized by the development of enhanced iron formulations designed to improve safety, efficacy, and patient convenience. Pharmaceutical companies are heavily investing in research to create advanced intravenous therapies that mitigate the drawbacks of traditional iron supplements, focusing on features such as extended dosing intervals, better tolerability, and minimized hypersensitivity risks. This shift not only enhances patient compliance but also marks a commitment to improving overall treatment outcomes. The ongoing push for novel formulations underscores a growing emphasis on patient-centric care within the intravenous iron drugs market, driving its growth and evolution.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Intravenous Iron Drugs Market Size by Product Type & CAGR (2025-2032)

• Market Overview
• Iron Dextran
• Iron Sucrose
• Ferric Carboxymaltose
• Other Product Types

Global Intravenous Iron Drugs Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Chronic Kidney Disease
• Inflammatory Bowel Disease
• Cancer
• Other Diseases

Global Intravenous Iron Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Intravenous Iron Drugs Market Size & CAGR (2025-2032)

• North America (Product Type, Indication, Distribution Channel)
  • US
  • Canada
• Europe (Product Type, Indication, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Indication, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Indication, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Indication, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharmacosmos A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius SE & Co. KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akebia Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rockwell Medical, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• American Regent, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AdvaCare Pharma (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shield Therapeutics plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galenica Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AMAG Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Covis Pharma GmbH (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations